These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35398999)

  • 1. Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.
    Rekik A; Aissi M; Rekik I; Mhiri M; Frih MA
    Brain Behav; 2022 May; 12(5):e2573. PubMed ID: 35398999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
    Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
    Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    Bonacchi R; Meani A; Pagani E; Marchesi O; Filippi M; Rocca MA
    J Neurol; 2022 Jul; 269(7):3841-3857. PubMed ID: 35230471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
    Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C
    JAMA Neurol; 2022 Jul; 79(7):682-692. PubMed ID: 35575778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxel-based analysis of gray matter relaxation rates shows different correlation patterns for cognitive impairment and physical disability in relapsing-remitting multiple sclerosis.
    Cassiano MT; Lanzillo R; Alfano B; Costabile T; Comerci M; Prinster A; Moccia M; Megna R; Morra VB; Quarantelli M; Brunetti A
    Neuroimage Clin; 2020; 26():102201. PubMed ID: 32062567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter data harmonization for regional brain atrophy and application in multiple sclerosis.
    Pagani E; Storelli L; Pantano P; Petsas N; Tedeschi G; Gallo A; De Stefano N; Battaglini M; Rocca MA; Filippi M;
    J Neurol; 2023 Jan; 270(1):446-459. PubMed ID: 36152049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grey matter atrophy in patients with benign multiple sclerosis.
    Niiranen M; Koikkalainen J; Lötjönen J; Selander T; Cajanus A; Hartikainen P; Simula S; Vanninen R; Remes AM
    Brain Behav; 2022 Jul; 12(7):e2679. PubMed ID: 35765699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.
    Bergsland N; Horakova D; Dwyer MG; Uher T; Vaneckova M; Tyblova M; Seidl Z; Krasensky J; Havrdova E; Zivadinov R
    Neuroimage Clin; 2018; 17():444-451. PubMed ID: 29159057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Marastoni D; Crescenzo F; Pisani AI; Zuco C; Schiavi G; Benedetti G; Ricciardi GK; Montemezzi S; Pizzini FB; Tamanti A; Calabrese M
    Mult Scler; 2022 Nov; 28(13):2090-2098. PubMed ID: 35765211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcortical gray matter atrophy is associated with cognitive deficit in multiple sclerosis but not in systemic lupus erythematosus patients.
    Kalinowska-Łyszczarz A; Pawlak MA; Pietrzak A; Pawlak-Buś K; Leszczyński P; Puszczewicz M; Majewski D; Paprzycki W; Kozubski W; Michalak S
    Lupus; 2018 Apr; 27(4):610-620. PubMed ID: 28992796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients.
    Tahedl M; Wiltgen T; Voon CC; Berthele A; Kirschke JS; Hemmer B; Mühlau M; Zimmer C; Wiestler B
    Brain Behav; 2023 Dec; 13(12):e3327. PubMed ID: 37961043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study.
    Damjanovic D; Valsasina P; Rocca MA; Stromillo ML; Gallo A; Enzinger C; Hulst HE; Rovira A; Muhlert N; De Stefano N; Bisecco A; Fazekas F; Arévalo MJ; Yousry TA; Filippi M
    AJNR Am J Neuroradiol; 2017 Jan; 38(1):18-24. PubMed ID: 27686487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.